ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2293

Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis?

Stephanie Shoop-Worrall1, Suzanne M Verstappen2, Janet E. McDonagh3, Wendy Thomson4 and Kimme L. Hyrich1, 1The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 2Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, 3Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, 4Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disability, juvenile idiopathic arthritis (JIA), Outcome measures, Outcomes and remission

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Identifying predictors for clinically inactive disease (CID) and sustained remission would allow rapid escalation of therapies for children less likely to achieve these states. This analysis assessed predictors of achievement of CID and sustained remission states over the first five years following diagnosis in children with JIA.

Methods: Children and young people enrolled in the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort, before January 2011, were selected if diagnosed with oligoarticular, RF-negative or RF-positive polyarticular JIA.

Components for CID and sustained remission according to i) Wallace’s preliminary criteria and ii) cJADAS10 were collected at annual follow-ups to five years according to CAPS protocol. Sustained remission was defined as two consecutive follow-ups in CID. Individual baseline core outcome variables (active joint count, limited joint count, physician’s global, parental global, functional ability (Childhood Health Assessment Questionnaire (CHAQ)) and ESR) were tested for predictive ability for i) CID at one year and ii) ever sustained remission within five years. Associations were tested in multivariable logistic regressions including all COVs, age and symptom duration at initial presentation, gender, ILAR subtype and recruiting centre. Multiple imputation accounted for missing predictor and outcome data.

Results: Of 832 children, 70% were female and the majority had oligoarticular JIA (68%). At one year, 31% had achieved CID according to Wallace’s preliminary criteria and 44% according to the cJADAS10 (26% CID on both). Within five years, 60% had ever achieved sustained remission on Wallace’s preliminary criteria and 66% on the cJADAS10 (52% sustained remission on both).

In multivariable analyses, an increase in 0.125 points (1 unit) on the CHAQ at baseline independently predicted 4% lower odds of CID on the cJADAS10 (95% CI 0.92, 0.99). No baseline COVs predicted CID on Wallace’s preliminary criteria. An increased year of age at initial presentation to paediatric rheumatology independently predicted 12% higher odds of sustained remission on Wallace’s preliminary criteria (95% CI 1.07, 1.17). In addition, one increased unit in CHAQ at baseline independently predicted 6% lower odds of sustained remission on both outcome measures (95% CI: Wallace: 0.91, 0.99; cJADAS10: 0.90, 0.98). Compared with oligoarticular JIA, children with RF-negative polyarticular and RF-positive polyarticular JIA had at least 49% and 68% lower odds of both sustained remission states, respectively. Gender and symptom duration to initial presentation were not independently associated with either outcome.

Conclusion: There were different predictors for CID on the cJADAS10 vs. Wallace’s preliminary criteria although similar predictors for sustained remission using either definition were identified. Children with poor functional ability, polyarticular JIA and younger age at initial presentation could be targeted with more aggressive treatment strategies than currently in practice to better control their disease.


Disclosure: S. Shoop-Worrall, None; S. M. Verstappen, None; J. E. McDonagh, None; W. Thomson, None; K. L. Hyrich, None.

To cite this abstract in AMA style:

Shoop-Worrall S, Verstappen SM, E. McDonagh J, Thomson W, Hyrich KL. Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/can-we-predict-achievement-of-clinically-inactive-disease-and-sustained-remission-in-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-we-predict-achievement-of-clinically-inactive-disease-and-sustained-remission-in-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology